1. Home
  2. NRIX vs VYX Comparison

NRIX vs VYX Comparison

Compare NRIX & VYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc. Common stock

NRIX

Nurix Therapeutics Inc. Common stock

HOLD

Current Price

$19.57

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo NCR Voyix Corporation

VYX

NCR Voyix Corporation

HOLD

Current Price

$9.67

Market Cap

1.6B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
VYX
Founded
2009
1881
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
NRIX
VYX
Price
$19.57
$9.67
Analyst Decision
Strong Buy
Buy
Analyst Count
13
6
Target Price
$26.08
$15.17
AVG Volume (30 Days)
1.8M
2.7M
Earning Date
01-27-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$83,687,000.00
$2,653,000,000.00
Revenue This Year
$58.38
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
48.32
N/A
52 Week Low
$8.18
$7.55
52 Week High
$22.95
$15.34

Technical Indicators

Market Signals
Indicator
NRIX
VYX
Relative Strength Index (RSI) 70.09 38.53
Support Level $16.02 $9.44
Resistance Level $22.50 $10.36
Average True Range (ATR) 1.33 0.39
MACD 0.32 0.02
Stochastic Oscillator 72.19 33.15

Price Performance

Historical Comparison
NRIX
VYX

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About VYX NCR Voyix Corporation

NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.

Share on Social Networks: